Structural and Antiviral Studies of the Human Norovirus GII.4 Protease.

ABSTRACT: Norovirus is the leading cause of acute gastroenteritis worldwide with a yearly reported 700 million cases driving a $60 billion global socioeconomic burden. With no United States Food and Drug Administration approved therapeutics and the chance for severe chronic infection and life-threatening complications, researchers have identified the protease as a potential target. However, drug development has focused on the norovirus GI.1 strain despite its accounting for less than 5% of all outbreaks. Our lab aims to change focus for norovirus drug design from GI.1 to the highly infective GII.4, responsible for more than 50% of all outbreaks worldwide. With the first published crystal structure of the norovirus GII.4 protease, we have identified several significant differences in the structure an

SUBMITTER: Muzzarelli KM 

PROVIDER: S-EPMC7717172 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature